person · Reporting owner

PATRICK DEVAL L

Disclosed activity across 8 companies

Tapewire entity: 13987
SEC CIK: 0001053466

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
American Well CorpAMWL · Entity 2112	Director	June 22, 2023	June 26, 2023
COCA COLA CO(KO) · Entity 2806	Executive Vice President	November 19, 2004	November 23, 2004
GreenLight Biosciences Holdings, PBCGRNA · Entity 111075	See Remarks	July 24, 2023	July 26, 2023
SpringWorks Therapeutics, Inc.SWTX · Entity 15910	Director	September 12, 2019	September 12, 2019
TWILIO INCTWLO · Entity 3109	Director	September 15, 2026	September 17, 2026
Toast, Inc.TOST · Entity 3272	Director	June 12, 2026	June 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

American Well Corp

Report date June 22, 2023 · Filed June 26, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	169,892	Reported balance After 2023-06-22 transaction · row 1 1 source row Row 1 · 2023-06-22 · Grant · Acquired 91,743 · Balance 169,892 F1: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date.
Class A Common StockSEC Table I · non-derivative	IndirectBy Wife	8,000	Reported balance Holding disclosure · report date 2023-06-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 8,000

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date.

COCA COLA CO

Report date November 19, 2004 · Filed November 23, 2004

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.25 par valueSEC Table I · non-derivative	Direct	39,084	Reported balance After 2004-11-19 transaction · row 1 1 source row Row 1 · 2004-11-19 · Sale · Disposed 13,100 · Balance 39,084
Common Stock, $.25 par valueSEC Table I · non-derivative	IndirectBy 401(k) plan	414	Reported balance Holding disclosure · report date 2004-11-19 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 414 F1: Shares credited to my account under The Coca-Cola Company Thrift & Investment Plan, a tax-qualified 401(k) plan, as of November 18, 2004.
Common Stock, $.25 par valueSEC Table I · non-derivative	IndirectBy daughter	50	Reported balance Holding disclosure · report date 2004-11-19 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 50
Hypothetical sharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectBy Deferred Compensation Plan	602	Reported balance Holding disclosure · report date 2004-11-19 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 602 F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company. F3: There is no data applicable with respect to the hypothetical shares. F4: Excess 401(k) as of November 18, 2004.
Hypothetical sharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectBy Supplemental Benefit Plan	2,183	Reported balance Holding disclosure · report date 2004-11-19 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 2,183 F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company. F3: There is no data applicable with respect to the hypothetical shares. F5: As of November 18, 2004.

Filing footnotes · ownership attribution and instrument terms

F1: Shares credited to my account under The Coca-Cola Company Thrift & Investment Plan, a tax-qualified 401(k) plan, as of November 18, 2004.

F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company.

F3: There is no data applicable with respect to the hypothetical shares.

F4: Excess 401(k) as of November 18, 2004.

F5: As of November 18, 2004.

GreenLight Biosciences Holdings, PBC

Report date July 24, 2023 · Filed July 26, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2023-07-24 transaction · row 1 1 source row Row 1 · 2023-07-24 · Other · Disposed 172,500 · Balance 0 F1: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent.

SpringWorks Therapeutics, Inc.

Report date September 12, 2019 · Filed September 12, 2019

This filing explicitly reported no securities owned.

TWILIO INC

Report date September 15, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	19,055	Reported balance After 2026-09-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-15 · Grant · Acquired 337 · Balance 19,055 F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2: Includes RSUs that have been deferred by the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant.

F2: Includes RSUs that have been deferred by the Reporting Person.

Toast, Inc.

Report date June 12, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Exercise / conversion · Disposed 5,256 · Balance 0 F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F2: The RSUs vested in full on June 12, 2026. F3: Not Applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	8,888	Reported balance After 2026-06-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-12 · Grant · Acquired 8,888 · Balance 8,888 F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F5: The RSUs shall vest in full on the earlier of 1) June 12, 2027 and 2) the next annual meeting of the Issuer's stockholders following the grant date. F3: Not Applicable.
Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	14,968	Reported balance After 2026-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-12 · Exercise / conversion · Acquired 5,256 · Balance 14,968 F4: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member. F3: Not Applicable.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement.

F2: The RSUs vested in full on June 12, 2026.

F3: Not Applicable.

F4: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member.

F5: The RSUs shall vest in full on the earlier of 1) June 12, 2027 and 2) the next annual meeting of the Issuer's stockholders following the grant date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cerevel Therapeutics Holdings, Inc.

Report date August 01, 2024 · Filed August 05, 2024

Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-08-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-08-01 · Disposition to issuer · Disposed 3,282 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-08-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-01 · Disposition to issuer · Disposed 49,794 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 9,037 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.75	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 625 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 15, 2026 Filed Sep 17, 2026 20:48 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	337	$0.00	$0.00	Disclosure SEC source: 0001053466-26-000004 · wk-form4_1789678127.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,055 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:31 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	391	$0.00	$0.00	Disclosure SEC source: 0001447669-26-000065 · wk-form4_1781728294.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,718 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:36 UTC	Toast, Inc. TOST · Entity 3272	GrantRestricted Stock Units · Derivative	8,888	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-26-000136 · wk-form4_1781642203.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Class A Common Stock · 8,888 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F5 · derivative.exercise_date: The RSUs shall vest in full on the earlier of 1) June 12, 2027 and 2) the next annual meeting of the Issuer's stockholders following the grant date. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:36 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionDeferred Stock Units · Derivative	5,256	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-26-000136 · wk-form4_1781642203.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,968 Underlying: Class A Common Stock · 5,256 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member. F4 · derivative.exercise_date: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:36 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionRestricted Stock Units · Derivative	5,256	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-26-000136 · wk-form4_1781642203.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 5,256 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F2 · derivative.exercise_date: The RSUs vested in full on June 12, 2026. F3 · derivative.expiration_date: Not Applicable. Read SEC document
March 15, 2026 Filed Mar 17, 2026 20:46 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	673	$0.00	$0.00	Disclosure SEC source: 0001053466-26-000002 · wk-form4_1773780394.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,327 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:43 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	627	$0.00	$0.00	Disclosure SEC source: 0001053466-25-000005 · wk-form4_1766007823.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,654 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
September 15, 2025 Filed Sep 17, 2025 20:35 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	763	$0.00	$0.00	Disclosure SEC source: 0001447669-25-000129 · wk-form4_1758141319.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,027 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
June 13, 2025 Filed Jun 17, 2025 20:33 UTC	Toast, Inc. TOST · Entity 3272	GrantRestricted Stock Units · Derivative	5,256	$0.00	$0.00	Disclosure SEC source: 0001650164-25-000232 · wk-form4_1750192377.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,256 Underlying: Class A Common Stock · 5,256 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs shall vest in full on the earlier of 1) June 13, 2026 and 2) the next annual meeting of the Issuer's stockholders following the grant date. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 09, 2025 Filed Jun 11, 2025 20:46 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	691	$0.00	$0.00	Disclosure SEC source: 0001447669-25-000095 · wk-form4_1749674758.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,264 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:49 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionDeferred Stock Units · Derivative	9,712	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-25-000219 · wk-form4_1749588576.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,712 Underlying: Class A Common Stock · 9,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable upon the Reporting Person's termination of service as a board member. F4 · derivative.exercise_date: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable upon the Reporting Person's termination of service as a board member. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:49 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionRestricted Stock Units · Derivative	9,712	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-25-000219 · wk-form4_1749588576.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs vested in full on June 6, 2025. F3 · derivative.expiration_date: Not Applicable. Read SEC document
March 15, 2025 Filed Mar 18, 2025 21:21 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	618	$0.00	$0.00	Disclosure SEC source: 0001447669-25-000047 · wk-form4_1742332857.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,573 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
March 13, 2025 Filed Mar 14, 2025 20:39 UTC	Toast, Inc. TOST · Entity 3272	SaleClass A Common Stock	34,222	$33.01	$1,129,531.33	Disclosure SEC source: 0001650164-25-000099 · wk-form4_1741984757.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,260 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.055 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this price range set forth in this footnote. Read SEC document
January 09, 2025 Filed Apr 23, 2026 20:38 UTC	Toast, Inc. TOST · Entity 3272	SaleClass A Common Stock	1,667	$36.95	$61,587.32	Disclosure SEC source: 0001650164-26-000096 · wk-form4_1776976714.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,815 F1 · balance_after: Does not reflect previously reported transactions that occurred after January 9, 2025. Read SEC document
December 15, 2024 Filed Dec 17, 2024 21:59 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	732	$0.00	$0.00	Disclosure SEC source: 0001447669-24-000204 · wk-form4_1734472779.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,955 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
September 15, 2024 Filed Sep 17, 2024 21:23 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,240	$0.00	$0.00	Disclosure SEC source: 0001447669-24-000146 · wk-form4_1726608216.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,223 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:21 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerStock Option (Right to Buy) · Derivative	49,794	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090790 · ownership.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,794 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:21 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerCommon Stock	10,461	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090790 · ownership.xml · nonDerivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F2 · price: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:21 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Disposition to issuerCommon Stock	3,282	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-090790 · ownership.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:38 UTC	Toast, Inc. TOST · Entity 3272	GrantRestricted Stock Units · Derivative	9,712	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-24-000214 · wk-form4_1718051902.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,712 Underlying: Class A Common Stock · 9,712 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F4 · derivative.exercise_date: The RSUs shall vest in full on the earlier of 1) June 6, 2025 and 2) the next annual meeting of the Issuer's stockholders following the grant date. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:38 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionRestricted Stock Units · Derivative	11,593	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-24-000214 · wk-form4_1718051902.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 11,593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs vested in full on June 6, 2024. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:38 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionClass A Common Stock	11,593	$0.00	$0.00	Disclosure SEC source: 0001650164-24-000214 · wk-form4_1718051902.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:48 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,234	$0.00	$0.00	Disclosure SEC source: 0001447669-24-000092 · wk-form4_1717793279.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,983 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:34 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantCommon Stock	10,461	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-070734 · ownership.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,743 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document
March 15, 2024 Filed Mar 19, 2024 21:28 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,195	$0.00	$0.00	Disclosure SEC source: 0001447669-24-000046 · wk-form4_1710883661.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,749 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
February 22, 2024 Filed Feb 26, 2024 21:22 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionRestricted Stock Units · Derivative	7,645	$0.00	$0.00	Disclosure SEC source: 0001650164-24-000079 · wk-form4_1708982509.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 7,645 shares Expires 2028-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments over three years following February 22, 2021. Read SEC document
February 22, 2024 Filed Feb 26, 2024 21:22 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionClass A Common Stock	7,645	Not disclosed	Not disclosed	Disclosure SEC source: 0001650164-24-000079 · wk-form4_1708982509.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. Read SEC document
December 15, 2023 Filed Dec 19, 2023 21:59 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,153	$0.00	$0.00	Disclosure SEC source: 0001447669-23-000251 · wk-form4_1703023177.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,554 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionStock Option (Right to Buy) · Derivative	30,130	$0.00 Strike: $12.62	$0.00	Disclosure SEC source: 0000950170-23-058836 · ownership.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,555 Underlying: Common Stock · 30,130 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021. Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	SaleCommon Stock	30,130	$25.00	$753,250.00	Disclosure SEC source: 0000950170-23-058836 · ownership.xml · nonDerivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,282 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. F2 · balance_after: Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan that were previously reported by the Reporting Person. Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionCommon Stock	30,130	$12.62	$380,240.60	Disclosure SEC source: 0000950170-23-058836 · ownership.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. F2 · balance_after: Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan that were previously reported by the Reporting Person. Read SEC document
September 15, 2023 Filed Sep 19, 2023 22:33 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,192	$0.00	$0.00	Disclosure SEC source: 0001447669-23-000193 · wk-form4_1695162776.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,401 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
July 24, 2023 Filed Jul 26, 2023 23:25 UTC	GreenLight Biosciences Holdings, PBC GRNA · Entity 111075	OtherCommon Stock, par value $0.0001 per share	172,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-23-034873 · ownership.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent. F1 · price: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent. Read SEC document
June 22, 2023 Filed Jun 26, 2023 21:10 UTC	American Well Corp AMWL · Entity 2112	GrantClass A Common Stock	91,743	$0.00	$0.00	Disclosure SEC source: 0001209191-23-039751 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,892 F1 · shares: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date. Read SEC document
June 12, 2023 Filed Jun 14, 2023 21:14 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,310	$0.00	$0.00	Disclosure SEC source: 0001447669-23-000129 · wk-form4_1686777245.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,209 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:30 UTC	Toast, Inc. TOST · Entity 3272	GrantRestricted Stock Units · Derivative	11,593	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-23-000228 · wk-form4_1686601826.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,593 Underlying: Class A Common Stock · 11,593 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs shall vest in full on the earlier of 1) June 8, 2024 and 2) the next annual meeting of the Issuer?s stockholders following the grant date. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	13,780	$0.00 Strike: $32.60	$0.00	Disclosure SEC source: 0000899243-23-015180 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,780 Underlying: Common Stock · 13,780 shares Expires 2033-06-07 F2 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantCommon Stock	3,282	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-015180 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,282 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 02, 2023 Filed Jun 5, 2023 20:29 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionRestricted Stock Units · Derivative	11,292	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-23-000197 · wk-form4_1685996970.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 11,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs vested in full on June 2, 2023. F3 · derivative.expiration_date: Not Applicable. Read SEC document
June 02, 2023 Filed Jun 5, 2023 20:29 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionClass A Common Stock	11,292	$0.00	$0.00	Disclosure SEC source: 0001650164-23-000197 · wk-form4_1685996970.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. Read SEC document
March 15, 2023 Filed Mar 17, 2023 22:04 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,101	$0.00	$0.00	Disclosure SEC source: 0001447669-23-000065 · wf-form4_167909068399863.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,899 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
February 22, 2023 Filed Feb 24, 2023 21:55 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionRestricted Stock Units · Derivative	7,640	$0.00	$0.00	Disclosure SEC source: 0001650164-23-000065 · wf-form4_167727570261652.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,645 Underlying: Class A Common Stock · 7,640 shares Expires 2028-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments over three years following February 22, 2021. Read SEC document
February 22, 2023 Filed Feb 24, 2023 21:55 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionClass A Common Stock	7,640	Not disclosed	Not disclosed	Disclosure SEC source: 0001650164-23-000065 · wf-form4_167727570261652.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. Read SEC document
December 15, 2022 Filed Dec 19, 2022 22:59 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,565	$0.00	$0.00	Disclosure SEC source: 0001447669-22-000222 · wf-form4_167149073081149.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,798 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	5,600	Not disclosed Strike: $22.30	Not disclosed	Disclosure SEC source: 0000899243-22-033161 · doc4.xml · derivative · entry 6 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	5,600	Not disclosed Strike: $37.09	Not disclosed	Disclosure SEC source: 0000899243-22-033161 · doc4.xml · derivative · entry 5 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	5,247	Not disclosed Strike: $64.75	Not disclosed	Disclosure SEC source: 0000899243-22-033161 · doc4.xml · derivative · entry 4 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,247 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	625	Not disclosed Strike: $68.75	Not disclosed	Disclosure SEC source: 0000899243-22-033161 · doc4.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment. Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	3,600	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033161 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.